FI2790681T4 - Polymeerillä päällystettyjä proteiinimikrohiukkasia käsittävän pitkävaikutteisen farmaseuttisen formulaation valmistusmenetelmä käyttäen sumutuskuivausta - Google Patents
Polymeerillä päällystettyjä proteiinimikrohiukkasia käsittävän pitkävaikutteisen farmaseuttisen formulaation valmistusmenetelmä käyttäen sumutuskuivausta Download PDFInfo
- Publication number
- FI2790681T4 FI2790681T4 FIEP12795967.4T FI12795967T FI2790681T4 FI 2790681 T4 FI2790681 T4 FI 2790681T4 FI 12795967 T FI12795967 T FI 12795967T FI 2790681 T4 FI2790681 T4 FI 2790681T4
- Authority
- FI
- Finland
- Prior art keywords
- protein
- drying
- spray
- micronized
- polymer
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims 13
- 102000004169 proteins and genes Human genes 0.000 title claims 13
- 239000011859 microparticle Substances 0.000 title claims 4
- 229920000642 polymer Polymers 0.000 title claims 4
- 238000001694 spray drying Methods 0.000 title claims 4
- 239000008194 pharmaceutical composition Substances 0.000 title claims 3
- 238000004519 manufacturing process Methods 0.000 title claims 2
- 238000013265 extended release Methods 0.000 title 1
- 238000000034 method Methods 0.000 claims 11
- 239000002245 particle Substances 0.000 claims 7
- 239000007864 aqueous solution Substances 0.000 claims 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical group CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 3
- 239000001856 Ethyl cellulose Substances 0.000 claims 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims 2
- 229920001710 Polyorthoester Polymers 0.000 claims 2
- 229930006000 Sucrose Natural products 0.000 claims 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 2
- 108010081667 aflibercept Proteins 0.000 claims 2
- 229920002988 biodegradable polymer Polymers 0.000 claims 2
- 239000004621 biodegradable polymer Substances 0.000 claims 2
- 238000009835 boiling Methods 0.000 claims 2
- 229920001249 ethyl cellulose Polymers 0.000 claims 2
- 235000019325 ethyl cellulose Nutrition 0.000 claims 2
- 239000003960 organic solvent Substances 0.000 claims 2
- 239000002745 poly(ortho ester) Substances 0.000 claims 2
- 229950008882 polysorbate Drugs 0.000 claims 2
- 229920000136 polysorbate Polymers 0.000 claims 2
- 239000012460 protein solution Substances 0.000 claims 2
- 239000000243 solution Substances 0.000 claims 2
- 238000000527 sonication Methods 0.000 claims 2
- 239000007921 spray Substances 0.000 claims 2
- 239000005720 sucrose Substances 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 239000006185 dispersion Substances 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 239000008363 phosphate buffer Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Ophthalmology & Optometry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Materials For Medical Uses (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161561525P | 2011-11-18 | 2011-11-18 | |
| PCT/US2012/065735 WO2013075068A1 (en) | 2011-11-18 | 2012-11-18 | Polymer protein microparticles |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI2790681T4 true FI2790681T4 (fi) | 2023-05-04 |
Family
ID=47295198
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP12795967.4T FI2790681T4 (fi) | 2011-11-18 | 2012-11-18 | Polymeerillä päällystettyjä proteiinimikrohiukkasia käsittävän pitkävaikutteisen farmaseuttisen formulaation valmistusmenetelmä käyttäen sumutuskuivausta |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US20130129830A1 (https=) |
| EP (4) | EP2790681B9 (https=) |
| JP (5) | JP6267649B2 (https=) |
| KR (4) | KR102133352B1 (https=) |
| CN (2) | CN105688188A (https=) |
| AU (1) | AU2012340107B2 (https=) |
| BR (1) | BR112014011915B1 (https=) |
| CA (2) | CA2855749C (https=) |
| DK (3) | DK3384903T3 (https=) |
| ES (4) | ES2909777T3 (https=) |
| FI (1) | FI2790681T4 (https=) |
| HU (2) | HUE051644T2 (https=) |
| IL (4) | IL277958B2 (https=) |
| MX (2) | MX362286B (https=) |
| PL (3) | PL3574897T3 (https=) |
| PT (2) | PT3384903T (https=) |
| RU (2) | RU2642664C2 (https=) |
| SG (2) | SG10202103003RA (https=) |
| WO (1) | WO2013075068A1 (https=) |
| ZA (4) | ZA201403379B (https=) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012019168A2 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| RU2013120302A (ru) | 2010-10-01 | 2014-11-20 | Модерна Терапьютикс, Инк. | Сконструированные нуклеиновые кислоты и способы их применения |
| EP2691101A2 (en) | 2011-03-31 | 2014-02-05 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| RU2648950C2 (ru) | 2011-10-03 | 2018-04-02 | Модерна Терапьютикс, Инк. | Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение |
| PL3574897T3 (pl) | 2011-11-18 | 2022-05-09 | Regeneron Pharmaceuticals, Inc. | Postać użytkowa o przedłużonym uwalnianiu zawierająca mikrocząstki białka polimerowego do stosowania w ciele szklistym oka w leczeniu naczyniowych zaburzeń oczu |
| CN104114572A (zh) | 2011-12-16 | 2014-10-22 | 现代治疗公司 | 经修饰的核苷、核苷酸和核酸组合物 |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
| AU2013243948A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins associated with human disease |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| WO2014081507A1 (en) | 2012-11-26 | 2014-05-30 | Moderna Therapeutics, Inc. | Terminally modified rna |
| EP2971010B1 (en) | 2013-03-14 | 2020-06-10 | ModernaTX, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| US20160194368A1 (en) | 2013-09-03 | 2016-07-07 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| US20160194625A1 (en) | 2013-09-03 | 2016-07-07 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| JP2016538829A (ja) | 2013-10-03 | 2016-12-15 | モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 低密度リポタンパク質受容体をコードするポリヌクレオチド |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| EP3169693B1 (en) | 2014-07-16 | 2022-03-09 | ModernaTX, Inc. | Chimeric polynucleotides |
| JP7185526B2 (ja) * | 2015-12-16 | 2022-12-07 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | タンパク質微粒子の組成物及び製造方法 |
| RS63135B1 (sr) | 2015-12-23 | 2022-05-31 | Modernatx Inc | Postupci upotrebe polinukleotida koji kodiraju ox40 ligand |
| KR102799807B1 (ko) | 2015-12-30 | 2025-04-24 | 코디악 사이언시스 인코포레이티드 | 항체 및 이의 접합체 |
| US20190241658A1 (en) | 2016-01-10 | 2019-08-08 | Modernatx, Inc. | Therapeutic mRNAs encoding anti CTLA-4 antibodies |
| JP7285220B2 (ja) | 2017-05-18 | 2023-06-01 | モデルナティエックス インコーポレイテッド | 連結したインターロイキン－１２（ｉｌ１２）ポリペプチドをコードするポリヌクレオチドを含む脂質ナノ粒子 |
| EP3459529A1 (en) | 2017-09-20 | 2019-03-27 | Tillotts Pharma Ag | Preparation of sustained release solid dosage forms comprising antibodies by spray drying |
| JP7536640B2 (ja) | 2017-11-17 | 2024-08-20 | アムジエン・インコーポレーテツド | ＶＥＧＦＲ－Ｆｃ融合タンパク質製剤 |
| MX2020009152A (es) | 2018-03-02 | 2020-11-09 | Kodiak Sciences Inc | Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos. |
| CA3127228A1 (en) * | 2019-01-30 | 2020-08-06 | Amgen Inc. | Aflibercept attributes and methods of characterizing and modifying thereof |
| CN118718181A (zh) | 2019-06-05 | 2024-10-01 | 里珍纳龙药品有限公司 | 用于精确剂量递送的装置及方法 |
| CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| WO2021108548A1 (en) * | 2019-11-25 | 2021-06-03 | Regeneron Pharmaceuticals, Inc. | Sustained release formulations using non-aqueous emulsions |
| WO2022115588A1 (en) * | 2020-11-25 | 2022-06-02 | Regeneron Pharmaceuticals, Inc. | Sustained release formulations using non-aqueous membrane emulsification |
| CN115887760A (zh) * | 2022-11-21 | 2023-04-04 | 娜罗曼苏(杭州)医疗生物科技有限公司 | 一种注射用左旋聚乳酸制备工艺 |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
| WO2026080597A1 (en) * | 2024-10-08 | 2026-04-16 | Regeneron Pharmaceuticals, Inc. | Sustained delivery of biologics and non-aqueous manufacture of same |
Family Cites Families (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4210529A (en) | 1974-12-26 | 1980-07-01 | Midwest Research Institute | Blood compatible polymers and applications thereof |
| US4304767A (en) | 1980-05-15 | 1981-12-08 | Sri International | Polymers of di- (and higher functionality) ketene acetals and polyols |
| US4764364A (en) | 1986-02-25 | 1988-08-16 | S R I International | Method of preparing bioerodible polymers having pH sensitivity in the acid range and resulting product |
| US5104221A (en) | 1989-03-03 | 1992-04-14 | Coulter Electronics Of New England, Inc. | Particle size analysis utilizing polarization intensity differential scattering |
| ATE194384T1 (de) | 1989-09-12 | 2000-07-15 | Hoffmann La Roche | Tnf-bindende proteine |
| GB9107628D0 (en) * | 1991-04-10 | 1991-05-29 | Moonbrook Limited | Preparation of diagnostic agents |
| US6063910A (en) | 1991-11-14 | 2000-05-16 | The Trustees Of Princeton University | Preparation of protein microparticles by supercritical fluid precipitation |
| ES2107051T3 (es) | 1992-09-21 | 1997-11-16 | Upjohn Co | Formulaciones de proteinas de liberacion sostenida. |
| GB9415810D0 (en) * | 1994-08-04 | 1994-09-28 | Jerrow Mohammad A Z | Composition |
| DE69534701T2 (de) | 1994-09-23 | 2006-10-19 | Alexion Pharmaceuticals, Inc., Cheshire | Verfahren zur behandlung von entzündlichen gelenkerkrankungen |
| US6004549A (en) | 1994-12-14 | 1999-12-21 | Schering Corporation | Crystalline protein controlled release compositions |
| US6019968A (en) | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
| US5968543A (en) | 1996-01-05 | 1999-10-19 | Advanced Polymer Systems, Inc. | Polymers with controlled physical state and bioerodibility |
| US5985309A (en) | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| EP0913177A1 (de) | 1997-11-03 | 1999-05-06 | Roche Diagnostics GmbH | Verfahren zur Herstellung trockener, amorpher Produkte enthaltend biologisch aktive Materialien mittels Konvektionstrocknung, insbesondere Sprühtrocknung |
| ATE262926T1 (de) * | 1998-01-29 | 2004-04-15 | Poly Med Inc | Asorbierbare mikropartikel |
| US6284282B1 (en) | 1998-04-29 | 2001-09-04 | Genentech, Inc. | Method of spray freeze drying proteins for pharmaceutical administration |
| US6956021B1 (en) | 1998-08-25 | 2005-10-18 | Advanced Inhalation Research, Inc. | Stable spray-dried protein formulations |
| US6927044B2 (en) | 1998-09-25 | 2005-08-09 | Regeneron Pharmaceuticals, Inc. | IL-1 receptor based cytokine traps |
| US6223455B1 (en) * | 1999-05-03 | 2001-05-01 | Acusphere, Inc. | Spray drying apparatus and methods of use |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| US7070959B1 (en) | 1999-06-08 | 2006-07-04 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
| US7303746B2 (en) | 1999-06-08 | 2007-12-04 | Regeneron Pharmaceuticals, Inc. | Methods of treating eye disorders with modified chimeric polypeptides |
| US7306799B2 (en) | 1999-06-08 | 2007-12-11 | Regeneron Pharmaceuticals, Inc. | Use of VEGF inhibitors for treatment of eye disorders |
| WO2001030320A1 (en) | 1999-10-22 | 2001-05-03 | Amgen Inc. | Biodegradable microparticles with novel erythropoietin stimulating protein |
| FR2809309B1 (fr) * | 2000-05-23 | 2004-06-11 | Mainelab | Microspheres a liberation prolongee pour administration injectable |
| TWI283182B (en) | 2000-08-07 | 2007-07-01 | Nektar Therapeutics | Inhalable spray dried 4-helix bundle protein powders having minimized aggregation |
| CA2451185A1 (en) | 2001-06-21 | 2003-01-03 | Altus Biologics, Inc. | Spherical protein particles and methods of making and using them |
| EP1413310A1 (en) * | 2001-07-09 | 2004-04-28 | Yamanouchi Pharmaceutical Co. Ltd. | Sustained-release compositions for injection and process for producing the same |
| SG106672A1 (en) | 2002-03-08 | 2004-10-29 | Asml Netherlands Bv | Mask for use in lithography, method of making a mask, lithographic apparatus, and device manufacturing method |
| WO2003092665A2 (en) * | 2002-05-02 | 2003-11-13 | Massachusetts Eye And Ear Infirmary | Ocular drug delivery systems and use thereof |
| EP2460530A3 (en) | 2002-12-31 | 2012-08-29 | Althea Technologies, Inc. | Human growth hormone crystals and methods for preparing them |
| US20040208928A1 (en) * | 2003-04-15 | 2004-10-21 | Animal Technology Institute Taiwan | Method for preparing an orally administrable formulation for controlled release |
| JP5628467B2 (ja) | 2003-06-26 | 2014-11-19 | シヴィダ・ユーエス・インコーポレイテッドＰｓｉｖｉｄａ Ｕｓ， Ｉｎｃ． | 生体分解性徐放性ドラッグデリバリーシステム |
| DE10339197A1 (de) | 2003-08-22 | 2005-03-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Sprühgetrocknete amorphe Pulver mit geringer Restfeuchte und guter Lagerstabilität |
| DK1667790T3 (da) * | 2003-10-01 | 2007-09-24 | Debio Rech Pharma Sa | Apparat og fremgangsmåde til fremstilling af partikler |
| US20070059336A1 (en) | 2004-04-30 | 2007-03-15 | Allergan, Inc. | Anti-angiogenic sustained release intraocular implants and related methods |
| WO2005110374A1 (en) * | 2004-04-30 | 2005-11-24 | Allergan, Inc. | Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component |
| US7727962B2 (en) | 2004-05-10 | 2010-06-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Powder comprising new compositions of oligosaccharides and methods for their preparation |
| US7655758B2 (en) | 2004-08-17 | 2010-02-02 | Regeneron Pharmaceuticals, Inc. | Stable liquid IL-1 antagonist formulations |
| US7572893B2 (en) | 2004-08-17 | 2009-08-11 | Regeneron Pharmaceuticals, Inc. | IL-1 antagonist formulations |
| PT1778723E (pt) | 2004-08-17 | 2013-01-25 | Regeneron Pharma | Formulações de antagonista de il-1 |
| US20060110429A1 (en) | 2004-11-24 | 2006-05-25 | Therakine Corporation | Implant for intraocular drug delivery |
| JP4744533B2 (ja) | 2004-12-30 | 2011-08-10 | ドゥビエル カンパニー リミテッド | 噴霧乾燥高分子型コレクチン属タンパク質及びその製造方法 |
| CN102614134B (zh) | 2005-03-25 | 2016-09-07 | 瑞泽恩制药公司 | Vegf拮抗剂制剂 |
| US8168584B2 (en) | 2005-10-08 | 2012-05-01 | Potentia Pharmaceuticals, Inc. | Methods of treating age-related macular degeneration by compstatin and analogs thereof |
| US8877229B2 (en) | 2005-12-02 | 2014-11-04 | Eyetech Inc. | Controlled release microparticles |
| KR100722607B1 (ko) * | 2006-05-11 | 2007-05-28 | 주식회사 펩트론 | 분산성 및 주사 투여능이 향상된 서방성 미립구의 제조방법 |
| US7608261B2 (en) | 2006-06-16 | 2009-10-27 | Regeneron Pharmacuticals, Inc. | VEGF antagonist formulations suitable for intravitreal administration |
| DE102006030166A1 (de) * | 2006-06-29 | 2008-01-10 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Tempern |
| DE102006030164A1 (de) | 2006-06-29 | 2008-01-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Inhalative Pulver |
| EP1958622A1 (en) | 2006-11-07 | 2008-08-20 | Royal College of Surgeons in Ireland | Method of producing microcapsules |
| US20100318193A1 (en) | 2007-03-08 | 2010-12-16 | Desai Tejal A | Topographically engineered structures and methods for using the same in regenerative medicine applications |
| EP2164425B1 (en) | 2007-03-16 | 2015-10-28 | The Regents of The University of California | Nanostructure surface coated medical implants and methods of using the same |
| KR100805208B1 (ko) * | 2007-03-27 | 2008-02-21 | 주식회사 펩트론 | 엑센딘 함유 서방성 제제 조성물, 엑센딘 함유 서방성미립구 및 이의 제조 방법 |
| JP2010532749A (ja) * | 2007-06-07 | 2010-10-14 | サーモディクス ファーマシューティカルズ， インコーポレイテッド | 質量を削減した長時間作用剤形 |
| BRPI0821359A2 (pt) | 2007-12-21 | 2015-06-16 | Merck Patent Ges Mit Beschränkter Haftung | Microcápsulas de lipídeos sólidas contendo hormônio de crescimento no núcleo sólido interno |
| WO2009090189A1 (en) | 2008-01-15 | 2009-07-23 | Abbott Gmbh & Co.Kg | Powdered protein compositions and methods of making same |
| US8399006B2 (en) | 2009-01-29 | 2013-03-19 | Forsight Vision4, Inc. | Posterior segment drug delivery |
| US8623395B2 (en) | 2010-01-29 | 2014-01-07 | Forsight Vision4, Inc. | Implantable therapeutic device |
| WO2010111132A2 (en) * | 2009-03-27 | 2010-09-30 | Bend Research, Inc. | Spray-drying process |
| CN101559041B (zh) | 2009-05-19 | 2014-01-15 | 中国科学院过程工程研究所 | 粒径均一的多肽药物缓释微球或微囊制剂及制备方法 |
| JP5816170B2 (ja) | 2009-06-26 | 2015-11-18 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体 |
| US8417452B2 (en) | 2009-08-19 | 2013-04-09 | General Motors Llc | System for providing information to an operator of a vehicle |
| CA2776472A1 (en) * | 2009-10-01 | 2011-04-07 | Evonik Degussa Corporation | Microparticle compositions and methods for treating age-related macular degeneration |
| JO3417B1 (ar) | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
| JOP20190250A1 (ar) | 2010-07-14 | 2017-06-16 | Regeneron Pharma | صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب |
| SI2600812T1 (sl) | 2010-08-05 | 2021-12-31 | ForSight Vision4, Inc., | Naprava za zdravljenje očesa |
| EP3861969A1 (en) | 2010-08-05 | 2021-08-11 | ForSight Vision4, Inc. | Injector apparatus for drug delivery |
| BR112013008366B1 (pt) | 2010-10-06 | 2022-02-08 | Regeneron Pharmaceuticals, Inc | Formulações farmacêuticas líquidas estáveis contendo anticorpos anti-receptor de interleucina-4 humana alfa, e recipiente contendo as referidas formulações |
| CN103547255B (zh) | 2011-04-14 | 2018-07-06 | 加利福尼亚大学董事会 | 多层薄膜药物递送装置以及其制造和使用方法 |
| AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| PL3574897T3 (pl) | 2011-11-18 | 2022-05-09 | Regeneron Pharmaceuticals, Inc. | Postać użytkowa o przedłużonym uwalnianiu zawierająca mikrocząstki białka polimerowego do stosowania w ciele szklistym oka w leczeniu naczyniowych zaburzeń oczu |
| NZ701915A (en) | 2012-05-18 | 2016-11-25 | Genentech Inc | High-concentration monoclonal antibody formulations |
| BR112014029760A2 (pt) | 2012-05-30 | 2017-06-27 | Univ California | dispositivos de distribuição de agente bioativo e métodos para fazer e usar os mesmos |
| US9463177B2 (en) | 2012-09-10 | 2016-10-11 | The Regents Of The University Of California | Compounds and methods for modulating vascular injury |
| EP2976107B1 (en) | 2013-03-19 | 2019-02-20 | ASIT BioTech s.a. | Allergen preparation |
| WO2016010924A1 (en) | 2014-07-14 | 2016-01-21 | Amgen Inc. | Crystalline antibody formulations |
| WO2017066554A1 (en) | 2015-10-16 | 2017-04-20 | Regeneron Pharmaceuticals, Inc. | Stable protein compositions |
| CR20180310A (es) | 2015-11-05 | 2018-11-30 | Basf Se | Oxadiazoles sustituidos para combatir hongod fitopatógenos |
| WO2017081641A1 (en) | 2015-11-13 | 2017-05-18 | Novartis Ag | Novel pyrazolo pyrimidine derivatives |
| TW201731867A (zh) | 2015-12-02 | 2017-09-16 | 賽諾菲公司 | Ｆｇｆ２１變異體 |
| MX2018005383A (es) | 2015-12-07 | 2018-08-16 | Acetate Int Llc | Composiciones formadoras de pelicula de acetato de celulosa. |
| CA3008006C (en) | 2015-12-15 | 2024-04-09 | Merck Sharp & Dohme Corp. | Biaryl monobactam compounds and methods of use thereof for the treatment of bacterial infections |
| JP7185526B2 (ja) | 2015-12-16 | 2022-12-07 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | タンパク質微粒子の組成物及び製造方法 |
-
2012
- 2012-11-18 PL PL19180351T patent/PL3574897T3/pl unknown
- 2012-11-18 EP EP12795967.4A patent/EP2790681B9/en active Active
- 2012-11-18 ES ES19180351T patent/ES2909777T3/es active Active
- 2012-11-18 JP JP2014542536A patent/JP6267649B2/ja active Active
- 2012-11-18 CN CN201610035281.3A patent/CN105688188A/zh active Pending
- 2012-11-18 KR KR1020147014549A patent/KR102133352B1/ko active Active
- 2012-11-18 CA CA2855749A patent/CA2855749C/en active Active
- 2012-11-18 EP EP18173299.1A patent/EP3384903B1/en active Active
- 2012-11-18 SG SG10202103003RA patent/SG10202103003RA/en unknown
- 2012-11-18 IL IL277958A patent/IL277958B2/en unknown
- 2012-11-18 CN CN201280056324.6A patent/CN103957898B/zh active Active
- 2012-11-18 IL IL303832A patent/IL303832A/en unknown
- 2012-11-18 AU AU2012340107A patent/AU2012340107B2/en active Active
- 2012-11-18 ES ES12795967T patent/ES2775104T5/es active Active
- 2012-11-18 EP EP19180351.9A patent/EP3574897B1/en active Active
- 2012-11-18 PL PL18173299T patent/PL3384903T3/pl unknown
- 2012-11-18 MX MX2014005997A patent/MX362286B/es active IP Right Grant
- 2012-11-18 SG SG11201402152YA patent/SG11201402152YA/en unknown
- 2012-11-18 PT PT181732991T patent/PT3384903T/pt unknown
- 2012-11-18 RU RU2014124682A patent/RU2642664C2/ru active
- 2012-11-18 ES ES18173299T patent/ES2810003T3/es active Active
- 2012-11-18 FI FIEP12795967.4T patent/FI2790681T4/fi active
- 2012-11-18 WO PCT/US2012/065735 patent/WO2013075068A1/en not_active Ceased
- 2012-11-18 RU RU2018101248A patent/RU2768492C2/ru active
- 2012-11-18 KR KR1020227014819A patent/KR20220063293A/ko active Pending
- 2012-11-18 ES ES22150172T patent/ES2985784T3/es active Active
- 2012-11-18 KR KR1020217004470A patent/KR20210021112A/ko not_active Ceased
- 2012-11-18 DK DK18173299.1T patent/DK3384903T3/da active
- 2012-11-18 US US13/680,069 patent/US20130129830A1/en not_active Abandoned
- 2012-11-18 HU HUE18173299A patent/HUE051644T2/hu unknown
- 2012-11-18 KR KR1020207003704A patent/KR102218223B1/ko active Active
- 2012-11-18 BR BR112014011915-5A patent/BR112014011915B1/pt active IP Right Grant
- 2012-11-18 EP EP22150172.9A patent/EP4026543B1/en active Active
- 2012-11-18 DK DK19180351.9T patent/DK3574897T3/da active
- 2012-11-18 CA CA3076725A patent/CA3076725A1/en active Pending
- 2012-11-18 PT PT191803519T patent/PT3574897T/pt unknown
- 2012-11-18 PL PL12795967.4T patent/PL2790681T5/pl unknown
- 2012-11-18 DK DK12795967.4T patent/DK2790681T4/da active
- 2012-11-18 HU HUE12795967A patent/HUE048597T2/hu unknown
-
2014
- 2014-04-29 IL IL232328A patent/IL232328B/en active IP Right Grant
- 2014-05-12 ZA ZA2014/03379A patent/ZA201403379B/en unknown
- 2014-05-16 MX MX2019000382A patent/MX2019000382A/es unknown
-
2017
- 2017-03-06 US US15/450,335 patent/US11291636B2/en active Active
- 2017-08-02 JP JP2017149732A patent/JP6549653B2/ja active Active
-
2018
- 2018-01-05 ZA ZA2018/00078A patent/ZA201800078B/en unknown
- 2018-10-28 IL IL262651A patent/IL262651B/en active IP Right Grant
-
2019
- 2019-04-19 JP JP2019079952A patent/JP6727372B2/ja active Active
-
2020
- 2020-02-05 ZA ZA2020/00742A patent/ZA202000742B/en unknown
- 2020-06-30 JP JP2020112359A patent/JP7217247B2/ja active Active
-
2022
- 2022-02-22 US US17/677,282 patent/US11951216B2/en active Active
-
2023
- 2023-01-23 JP JP2023007775A patent/JP7542090B2/ja active Active
-
2024
- 2024-01-30 ZA ZA2024/00983A patent/ZA202400983B/en unknown
- 2024-03-07 US US18/598,435 patent/US20240207194A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI2790681T4 (fi) | Polymeerillä päällystettyjä proteiinimikrohiukkasia käsittävän pitkävaikutteisen farmaseuttisen formulaation valmistusmenetelmä käyttäen sumutuskuivausta | |
| Pearnchob et al. | Dry polymer powder coating and comparison with conventional liquid-based coatings for Eudragit® RS, ethylcellulose and shellac | |
| JP2012236837A5 (https=) | ||
| CA2558535A1 (en) | A stable pharmaceutical composition comprising an acid labile drug | |
| JP2014515356A5 (https=) | ||
| CN1222277C (zh) | 基于活性成分的微颗粒及其制造方法 | |
| CN102580106B (zh) | 一种pH敏感型聚电解质微囊给药载体的制备方法 | |
| WO2007138022A2 (en) | Lipoic acid pellets | |
| CN103385856B (zh) | 一种制备5-ala或其衍生物纳米颗粒的方法 | |
| CN109464423A (zh) | 海藻酸钙-壳聚糖微球及制备方法、载药海藻酸钙-壳聚糖及制备方法 | |
| HRP20200780T1 (hr) | Formulacija za kontrolirano otpuštanje hidrokortizona | |
| EP2501368B1 (en) | A process for converting a solid (meth)acrylate copolymer into a dispersed form by means of a dispersing agent | |
| CN101724207B (zh) | 聚苯乙烯/金复合粒子的制备方法 | |
| Alai et al. | A novel nanoparticulate system for sustained delivery of acid-labile lansoprazole | |
| CN104997757A (zh) | 雷贝拉唑钠肠溶微丸胶囊及其制备方法 | |
| CN108261402A (zh) | 盐酸安非他酮肠溶缓释片的速释片芯制备方法 | |
| CN105081344A (zh) | 一种纳米金颗粒的制备工艺 | |
| CN102935235B (zh) | 一种改性酪素载药缓释薄膜的制备方法 | |
| CN105726488B (zh) | 含有呼吸道合胞病毒抑制剂的肠溶微丸及其制备方法 | |
| RU2611367C1 (ru) | Способ получения нанокапсул антибиотиков тетрациклинового ряда в альгинате натрия | |
| US20060115526A1 (en) | Venlafaxine compositions comprising pellets with double layer coating | |
| SK12422000A3 (sk) | Spôsob výroby zapuzdrených sférických zŕn granulátu | |
| JP5780293B2 (ja) | 新規なコーティング系 | |
| CN107823146B (zh) | 一种双层核壳结构亚微米级pH/温度敏感载药微球的制备方法 | |
| RU2627580C2 (ru) | Способ получения нанокапсул антибиотиков тетрациклинового ряда в конжаковой камеди |